Estrogen Therapy in 2017

  • Nastassia Sylvestre
  • Catherine KimEmail author
Women and Heart Disease (E. Jackson, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Women and Heart Disease


Purpose of Review

After the publication of the Women’s Health Initiative, there was a dramatic reduction in prescriptions for menopausal hormonal therapy (MHT). We performed a literature search and reviewed major society guidelines to discuss recommendations and practice since 2010 regarding MHT.

Recent Findings

While not recommended for management and prevention of chronic diseases, MHT offers relief for bothersome menopausal symptoms. For vasomotor symptoms and vaginal atrophy, low-dose estrogen therapy (systemic and vaginally, respectively) provided effective relief of symptoms and improved quality of life. For cognitive and mood related effects, MHT had little benefit.


Consideration of MHT for menopausal symptoms should be part of an overall strategy including lifestyle recommendations regarding diet, exercise, smoking cessation, and safe levels of alcohol consumption for maintaining the health of peri- and postmenopausal women. Future research should examine best practices for tapering therapy and monitoring for endometrial cancer risk.


Estrogen therapy Estrogen replacement Menopausal symptoms Hot flashes Vaginal atrophy 


Compliance with Ethical Standards

Conflict of Interest

Drs Sylvestre & Kim have no conflicts of interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Sprague B, Trentham-Dietz A, Cronin K. A sustained decline in postmenopausal hormone use: results from the national health and nutrition examination survey, 1999–2010. J Obstet Gynecol. 2012;120(3):595–603.CrossRefGoogle Scholar
  2. 2.
    Manson J, Chlebowski R. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA. 2013;310(13):1353–68.CrossRefPubMedGoogle Scholar
  3. 3.
    Anderson G, Limacher M. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initative randomized controlled trial. JAMA. 2004;294(14):1701–12.Google Scholar
  4. 4.
    Rossouw J, Anderson G, Prentice R. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initative randomized controlled trial. JAMA. 2002;288:321–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Brunner R, Aragakl A, Barnabel V, Cochrane B, Gass M, Hendrix S, et al. Menopausal symptom experience before and after stopping estrogen therapy in the women’s health initiative randomized placebo-controlled trial. Menopause. 2010;17(5):946–54.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gleason C. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from teh randomized controlled KEEPS—cognitive and affective study. PLoS. 2015;25:e1001833.CrossRefGoogle Scholar
  7. 7.
    •• Hodis H, Mack W, Henderson V, Shoupe D, Budoff M, Hwang-Levine J, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374:1221–31. This randomized trial demonstrated that randomization to transdermal estradiol had little impact on coronary artery calcification, suggesting that estradiol therapy might not increase risk of cardiovascular disease events.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, et al. KEEPS: the kronos early estrogen prevention study. Climacteric. 2005;8(1):3–12.CrossRefPubMedGoogle Scholar
  9. 9.
    North American Menopause Society. The 2012 hormone therapy position statement of the North American Menopause Society. Menopause. 2012;19(3):257–71.CrossRefGoogle Scholar
  10. 10.
    Pinkerton J, Constantine G. Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey. Menopause. 2016;23(4):359–67.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Bhavnani B, Stanczyk F. Misconception and concerns about bioidentical hormones used for custom-compounded hormone therapy. J Clin Endocrinol Metab. 2012;97(3):756–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Cirigliano M. Bioidentical hormone therapy: a review of the evidence. J Women’s Health. 2007;16(5):600–31.CrossRefGoogle Scholar
  13. 13.
    Santoro N, Braunstein G, Butts C, Martin K, McDermott M, Pinkerton J. Compounded bioidentical hormones in endocrinology practice: an endocrine soceity scientific statement. J Clin Endocrinol Metab. 2016;101(4):1318–43.CrossRefPubMedGoogle Scholar
  14. 14.
    Boothby L, Doering P, Kipersztok S. Bioidentical hormone therapy: a review. Menopause. 2004;11:365–7.CrossRefGoogle Scholar
  15. 15.
    Mohammed K, Abu Dabrh A, Benkhadra KN, Al Nofal A, Carranza Leon B, Prokop L, et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:4012–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Goodman M. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Women’s Health. 2012;21(2):161–9.CrossRefGoogle Scholar
  17. 17.
    Corbelli J, Shaikh N, Wessel C, Hess R. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause. 2014;22(1):114–21.CrossRefGoogle Scholar
  18. 18.
    Woods N, MItchell E. Symptoms during the perimenopause: prevalence, severity, trajectory, and signficance in women’s lives. Am J Med. 2005. doi: 10.1016/j.amjmed.2005.09.031.PubMedGoogle Scholar
  19. 19.
    Dennerstein L, Dudley EH, Hopper JL, Guthrie JB, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96(3):351–8.PubMedGoogle Scholar
  20. 20.
    Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52–86.CrossRefPubMedGoogle Scholar
  21. 21.
    Gold E, Colvin A, Avis N, Bromberger J, Greendale G, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition; study of women’s health across the nation. Am J Public Health. 2006;96(7):1226–35.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Randolph J, Sowers M, Bondarenko I, Gold E, Greendale G, Bromberger J, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab. 2005;90(11):6106–12.CrossRefPubMedGoogle Scholar
  23. 23.
    Thurston R, Joffe H. Vasomotor symptoms and menopause: findings from the study of women’s health across the nation. Obstet Gynecol Clin N Am. 2011;38(3):489–501.CrossRefGoogle Scholar
  24. 24.
    Harlow S, Gass M, Hall J, Lobo R, Maki P, Rebar R, et al. Executive summary of the stages of reproductive aging workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    McKinlay S, Brambilla D, Posner J. The normal menopause transition. Maturitas. 1992;14(2):103.CrossRefPubMedGoogle Scholar
  26. 26.
    Fantasia H, Sutherland M. Hormone therapy for the management of menopause symptoms. J Obstet Gynecol Neonatal Nurs. 2014;43:226–35.CrossRefGoogle Scholar
  27. 27.
    Kravitz H, Ganz P, Bromberger J, Powell L, Sutton-Tyrrell KM, Meyer PM. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause. 2003;10(1):19–28.PubMedGoogle Scholar
  28. 28.
    Weber M, Maki P, McDermott M. Cognition and mood in perimenopause: a systematic review and meta-analysis. J Steroid Biochem Mol Biol. 2014;142:90–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Schaafsma M, HOmewood J, Taylor A. Subjective cognitive complaints at menopause associated with declines in performance of verbal memory and attnetional processes. Climacteric. 2009;13:1–15.CrossRefGoogle Scholar
  30. 30.
    Weber M, Rubin L, Maki P. Cognition in perimenopause: the effect of transition stage. Menopause. 2013;20(5):511.PubMedGoogle Scholar
  31. 31.
    Hedrick R, Ackerman R, Koltun W, Halvorsen M. Estradiol gel 0.1% relieves vasomotor symptoms independent of age, ovarian status, or uterine status. Menopause. 2010;17(6):1167–73.CrossRefPubMedGoogle Scholar
  32. 32.
    Demetrio F, Renno JJ, Gianfaldoni A, Goncalves M, Halbe H, Filho A, et al. Effect of estrogen replacement therapy on symptoms of depression and anxiety in non-depressive menopausal women: a randomized double-blind, controlled study. Arch Womens Ment Health. 2011;14(6):479–86.CrossRefPubMedGoogle Scholar
  33. 33.
    • Archer D, Pickar J, MacAllister D, Warren M. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. Menopause. 2012;19(6):622–9. This double-blind, randomized, placebo-controlled, multicenter, 12-week trial aimed to determine the efficacy, safeter, and lowest practical dose of a transdermal estradiol gel in the treatment of symptomatic postmenopausal women. The study assessed the frequency of moderate to severe hot flushes at 4 and 12 weeks of therapy.CrossRefPubMedGoogle Scholar
  34. 34.
    • Veerus P, Hovi S, Sevon T, Hunter M, Hemminki E. The effect of homrone therapy on women’s quality of life in the first year of the Estonian Postmenopausal Hormone Therapy Trial. BMC Res Notes. 2012;5:176. This randomized trial aimed to analyze the impact of hormonal therapy on different aspects of symptom experience and quality of life. Women were randomized into three different treatment arms and one non-treatment arms. This study confirms the use of hormone therapy for the management of menopausal symptoms.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Savolainen-Peltonen H, Hautamaki H, Tuomikoski P, Ylikorkala O, Mikkola T. Health-related quality of life in women with or without hot flashes: a randomized placebo-controlled trial with hormone therapy. Menopause. 2013;21(7):732–9.CrossRefGoogle Scholar
  36. 36.
    Joffe H, Guthrie K, LaCroix A. Randomized controlled trial of low-dose estradiol and the SNRI venlafaxine for vasomotor symptoms. JAMA Intern Med. 2014;174(7):1058–66.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Nappi R, Panay N, Bruyniks N, Castelo-Branco C, De Villiers T, Simon J. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 2015;18:233–40.CrossRefPubMedGoogle Scholar
  38. 38.
    Caan B, LaCroix A, Joffe H, Guthrie K, Larson J, Carpenter J, et al. Effects of estrogen or venlafaxine on menopause related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause. 2015;22(6):607–15.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Illston J, Wheeler T, Parker C, Conner M, Burgio K, Goode P, et al. Low-dose 17-beta-estradiol cream for vaginal atrophy in a cohort without prolapse: serum levels and vaginal response including tissue biomarkers associated with tissue remodeling. Maturitas. 2015;81(4):475–9.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Guthrie K, LaCroix A, Ensrud K, Joffe H, Newton K, Reed S, et al. Pooled analysis of six pharmacologic and nonpharmacologic interventions of vasomotor symptoms. Obstet Gynecol. 2015;126(2):413–22.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Archer D, Freeman E, Komm B, Ryan KY, Yu CR, Mirkin S, et al. Pooled analysis of the effects of conjugated estrogens/bazedoxifene on vasomotor symptoms in the selective estrogens, menopause, and response to therapy trials. J Women’s Health. 2016. doi: 10.1089/jwh.2015.5558.Google Scholar
  42. 42.
    Henderson V, St. John J, Hodis H, McCleary C, Stanczyk F, Shoupe D, et al. Cognitive effects of estradiol after menopase: a randomized trial of the timing hypothesis. Neurology. 2016;87:699–708.CrossRefPubMedGoogle Scholar
  43. 43.
    ACOG. Practice bulletin no 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202–16.CrossRefGoogle Scholar
  44. 44.
    NG Clearinghouse. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Rockville: Agency for Healthcare Research and Quality (AHRQ); 2013. Available from:
  45. 45.
    Stuenkel C, Davis S, Gompel A, Lumsden M, Murad M, Pinkerton J, et al. Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:3975–4011.CrossRefPubMedGoogle Scholar
  46. 46.
    Baber R, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of MedicineUniversity of MichiganAnn ArborUSA
  2. 2.Departments of Medicine, Obstetrics & Gynecology, and EpidemiologyUniversity of MichiganAnn ArborUSA

Personalised recommendations